Compare Bandwidth Inc (BAND) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bandwidth Inc vs Viatris Inc — how do they compare? Bandwidth Inc trades at $73.02 (market cap $2.36B), while Viatris Inc trades at $16.44 (market cap $18.99B). The key difference: Viatris Inc is far larger — about 8× Bandwidth Inc's market cap, and Viatris Inc pays a 2.94% dividend while Bandwidth Inc pays none. Which is the better fit depends on your goals.
| BAND | VTRS | |
|---|---|---|
Market Cap | $2.36B | $18.99B |
Sector | Technology | Health |
52-Week High | $78.44 | $17.39 |
52-Week Low | $12.82 | $8.74 |
Enterprise Value | $2.74B | $31.20B |
Dividend Yield | — | 2.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bandwidth (BAND) trades at $73.81, down 2.21% today, with strong technical momentum indicated by bullish moving averages. The company reported Q1 2026 EPS of $0.38, beating expectations of $0.32, while revenue reached $753.82 million in 2025. Analyst sentiment is positive with 12 buy ratings and a consensus price target of $71.67. Recent news highlights AI-driven growth in cloud communications and a $275 million convertible notes offering to fuel expansion.
The outlook for BAND is cautiously optimistic, driven by AI infrastructure demand and cloud communications growth. Key risks include negative profit margins and high valuation multiples. Investment opportunity lies in execution of AI initiatives, but investors should monitor earnings sustainability and competitive pressures in the technology sector.
Viatris (VTRS) trades at $16.39, up 0.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, with improving cash flow trends and a consensus price target of $20. Recent positive Phase 3 results for VR-205 and FDA acceptance of a new drug application highlight pipeline progress.
The outlook is mixed: strong analyst buy ratings and a 22% upside to target suggest value, but profitability challenges and high debt pose risks. Investors should weigh the potential from pipeline catalysts against ongoing margin pressure and competitive threats in the generic drug space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bandwidth Inc
Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.
Read more on BAND →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
